| eclitasertib (SAR443122) / Sanofi |
| Completed | 2 | 78 | Europe, Canada, US, RoW | SAR443122, Placebo | Sanofi | Cutaneous Lupus Erythematosus | 05/23 | 06/23 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | SAR443122, Placebo | Sanofi, sanofi research & development, sanofi research & development | Colitis Ulcerative | 02/26 | 12/26 | | |
| Active, not recruiting | 1/2 | 129 | Europe | Matched Placebo for Test | Sanofi-Aventis Research & Development, sanofi research & development, sanofi research & development | Colitis ulcerative | | | | |
| Completed | 1 | 15 | Europe | | Sanofi-Aventis Recherche & Developpement | Colitis ulcerative | | | | |
| oditrasertib (DNL788) / Denali Therap, Sanofi |
2021-004156-42: Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS) |
|
|
| Ongoing | 2 | 261 | Europe | SAR443820, Film-coated tablet | Sanofi-aventis recherche & développement, Sanofi-Aventis recherche & développement | Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
2022-000049-34: Phase 2 study of SAR443820 in participants with multiple sclerosis (MS) |
|
|
| Ongoing | 2 | 280 | Europe, RoW | SAR443820, [.], Film-coated tablet | Sanofi-aventis recherche & développement, SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT, Sanofi-Aventis recherche & développement | Multiple sclerosis, Multiple sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Terminated | 2 | 305 | Europe, Canada, Japan, US, RoW | SAR443820, Placebo | Sanofi, Sanofi-Aventis recherche & développement | Amyotrophic Lateral Sclerosis | 03/24 | 03/24 | | |
| Terminated | 2 | 174 | Europe, Canada, RoW | SAR443820, Placebo | Sanofi, Sanofi Aventis Recherche et Developpement | Multiple Sclerosis | 11/24 | 11/24 | | |
ACT16753, 2023-509078-45-00`2022-000049-34: A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period |
|
|
| Completed | 1/2 | 157 | Europe | Matched placebo for product, GADOBUTROL
, SAR443820 | Sanofi-Aventis Recherche & Developpement, Sanofi Aventis Recherche et Developpement | Multiple sclerosis | | | | |
NCT05795907: Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants |
|
|
| Completed | 1 | 84 | US | SAR443820, Placebo | Sanofi | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 07/21 | 07/21 | | |
NCT05797701: A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2) |
|
|
| Completed | 1 | 18 | US | SAR443820 | Sanofi | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 09/21 | 09/21 | | |
NCT05797753: A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B) |
|
|
| Completed | 1 | 16 | US | SAR443820, Erythromycin ethyl succinate, Itraconazole | Sanofi | Amyotrophic Lateral Sclerosis, Healthy Volunteer | 07/22 | 07/22 | | |
| GFH312 / GenFleet Therap |
NCT05618691: A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC) |
|
|
| Withdrawn | 2 | 100 | US | GFH312, Placebo | Zhejiang Genfleet Therapeutics Co., Ltd. | Intermittent Claudication, Peripheral Artery Disease | 12/23 | 05/24 | | |
| Completed | 1 | 76 | RoW | GFH312, Placebo | GenFleet Therapeutics (Australia) Pty Ltd. | Toxicity, Healthy | 05/22 | 10/22 | | |
NCT05991362: A Phase I Study of GFH312 in Healthy Chinese Subjects |
|
|
| Completed | 1 | 26 | RoW | GFH312 100 mg, GFH312, GFH312 200 mg, GFH312 120mg, Placebo | Zhejiang Genfleet Therapeutics Co., Ltd. | Healthy Volunteer | 02/23 | 05/23 | | |
| SIR2446 / Sironax |
| Completed | 1 | 114 | | | Sironax Aus Pty Ltd, Sironax Aus Pty Ltd | Degenerative disease, Inflammatory disease | | | | |
| ocadusertib (LY3871801) / Rigel Pharmaceuticals |
| Completed | 2 | 164 | Europe, US, RoW | LY3871801, Placebo | Eli Lilly and Company, Rigel Pharmaceuticals | Rheumatoid Arthritis | 12/25 | 04/26 | | |
2022-502994-40-00: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis |
|
|
| Recruiting | 1/2 | 62 | Europe | LY3871801_25g, Placebo to match LY3871801 | Eli Lilly & Co. | Rheumatoid Arthritis | | | | |
NCT05602675: A Drug Interaction Study of LY3871801 in Healthy Participants |
|
|
| Completed | 1 | 39 | US | LY3871801, Methotrexate, Warfarin, Dextromethorphan, Midazolam, Repaglinide | Eli Lilly and Company | Healthy | 03/23 | 03/23 | | |
NCT05960851: A Study of LY3871801 in Healthy Asian and Non-Asian Participants |
|
|
| Completed | 1 | 32 | US | LY3871801, Placebo | Eli Lilly and Company | Healthy | 10/23 | 10/23 | | |
NCT06049108: A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants |
|
|
| Completed | 1 | 8 | US | [14C]-LY3871801 | Eli Lilly and Company | Healthy | 11/23 | 11/23 | | |
| flizasertib (RG6287) / Roche |
NCT06602453 / 2024-513125-23-00: A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) |
|
|
| Terminated | 2 | 67 | Europe, Canada, US, RoW | GDC-8264, RO7288817, Placebo | Genentech, Inc., Genentech Inc. | Acute Kidney Injury | 03/26 | 03/26 | | |
GC45428, 2024-513125-23-00: A Study to Understand the ability and safety of GDC-8264 in Preventing kidney Injury and Major Adverse Kidney Events following Heart Surgery |
|
|
| Recruiting | 1/2 | 175 | Europe | Placebo: GDC-8264, GDC-8264 | Genentech Inc., Genentech Inc. | Patients with moderate to high risk for cardiac surgery associated- acute kidney injury (CSA-AKI) | | | | |
NCT05673876: A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) |
|
|
| Completed | 1 | 7 | US | GDC-8264 | Genentech, Inc. | Acute Graft-versus-host Disease | 01/24 | 01/24 | | |
| ABBV-668 IR / AbbVie |
NCT05570006: Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis |
|
|
| Completed | 2 | 30 | Europe, US | ABBV-668 | AbbVie | Ulcerative Colitis | 12/24 | 12/24 | | |
|
NCT06477926: A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants |
|
|
| Completed | 1 | 25 | US | ABBV-668 IR, ABBV-668 ER | AbbVie | Healthy Volunteers | 09/24 | 09/24 | | |
| OPM-101 / Oncodesign |
REVERT, NCT07040436: Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1 |
|
|
| Not yet recruiting | 1/2 | 41 | NA | OPM-101 | Oncodesign Precision Medicine | Advanced Melanoma | 09/27 | 12/27 | | |
